FDA Approved: JANUVIA — Supplemental Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

The FDA approved a supplemental application for Januvia (sitagliptin) from Merck Sharp & Dohme LLC, to the existing NDA for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Januvia (sitagliptin)

Snippet

SUPPL AP for JANUVIA (SITAGLIPTIN)